Respiratory syncytial virus infection+1
RecruitingPhase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years
Phase 2b Study of VXB-221 and VXB-213 Protein Vaccine for Prevention of Respiratory Syncytial Virus and Human Metapneumovirus Infections in Adults ≥60 Years
- Disease:Respiratory syncytial virus infectionMetapneumovirus infection
- Substances:VXB-213VXB-221
Spain- Participants:18–64 years · 65+ years · Healthy volunteers
- Substances:VXB-213
- Sponsor:Sanofi Pasteur Inc.











